Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 810M 709M 654M 604M 1.15B 77.22B 1.16B 7.81B 3.06B 38.04B 3.04B 2.97B 131B P/E 2026 *
12.4x
P/E 2027 * 12.6x
Enterprise Value 810M 709M 654M 604M 1.15B 77.22B 1.16B 7.81B 3.06B 38.04B 3.04B 2.97B 131B EV / Sales 2026 *
2.93x
EV / Sales 2027 * 2.45x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rigel Pharmaceuticals, Inc.

1 day-2.77%
1 week+9.89%
Current month+8.77%
1 month+37.66%
3 months+45.72%
6 months+4.19%
Current year-0.65%
1 week 38.8
Extreme 38.8
43.99
1 month 31.8
Extreme 31.8
43.99
Current year 24.95
Extreme 24.95
49.1
1 year 18.65
Extreme 18.65
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
06-21Sell

Director

-2,500 0.0135%
06-16Free

Chief Executive Officer

31,700 0.1713%
06-16Free

Chief Technology Officer

16,769 0.0906%
Change 5-day change 1-year change 3-year change Capi.($)
-2.77%+9.89%+117.09%+222.35% 810M
-2.33%-2.09%+50.33%+162.29% 1,085B
-0.82%-2.30%+62.97%+61.11% 624B
-0.73%-4.98%+27.22%+84.46% 442B
+0.33%-1.43%+29.46%+26.92% 332B
-0.02%-2.92%+27.40%+46.37% 282B
-3.89%-11.72%+23.86%+26.94% 277B
+0.66%-2.94%-27.27%-39.99% 217B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 167B
Average -0.99%-0.47%+34.54%+72.37% 362.27B
Weighted average by Cap. -0.46%-1.06%+36.04%+81.87%

Financials

2026 *2027 *
Net sales 277M 242M 223M 206M 391M 26.38B 398M 2.67B 1.05B 12.99B 1.04B 1.02B 44.72B 331M 290M 267M 247M 468M 31.56B 476M 3.19B 1.25B 15.54B 1.24B 1.22B 53.5B
Net income 70.19M 61.5M 56.7M 52.39M 99.34M 6.69B 101M 677M 266M 3.3B 264M 258M 11.35B 79.07M 69.27M 63.87M 59.02M 112M 7.54B 114M 763M 299M 3.71B 297M 290M 12.78B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-07-10 US$42.55 -2.77% 461,036
26-07-09 US$43.76 +1.93% 320,108
26-07-08 US$42.93 +0.87% 313,678
26-07-07 US$42.56 +5.73% 744,397
26-07-06 US$40.26 +3.96% 449,679
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
43.76USD
Average target price
54.20USD
Spread / Average Target
+23.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock